Walking Fish Adds $23 Million to Series A Financing to Advance B Cell Therapies for Multiple Diseases
February 17, 2022
Walking Fish Therapeutics, a company focused on B cell therapeutics, completed an oversubscribed series A financing, raising a total of $73 million, which includes $50 million announced when the company launched in September 2021.
Northpond Ventures and First Spark Ventures co-led the additional investment, with support from Terra Magnum Capital Partners.
Proceeds from the financing will be used to advance a pipeline of B cell therapeutics for oncology, rare disease, regenerative medicine, autoimmune disease, and recombinant antibody production.
Walking Fish has made critical advances in developing a platform to harness B cells’ capability to activate the immune system in the treatment of cancer, and to serve as in vivo protein factories that produce replacement proteins for rare deficiency diseases, regenerative proteins, and engineered antibodies.
The executive team includes co- founder and CEO Lewis “Rusty” Williams, who was also the founder of Five Prime Therapeutics (now part of Amgen).
Since the launch of the series A financing in September, Walking Fish’s platform for protein factories and oncology applications has continued to demonstrate positive preclinical data across multiple indications. The additional proceeds will accelerate platform development and further establish Walking Fish as the leader in the rapidly emerging B cell therapeutics field.
“Recent Walking Fish innovations in B cell engineering and manufacturing have enabled expansion of our pipeline to include new product opportunities,” said Lewis “Rusty” Williams, co-founder and CEO of Walking Fish Therapeutics. “We believe strongly in the power of B cell therapeutics in applications spanning oncology to protein deficiency diseases, and we are confident the support of our new investors will enable us to further advance this emerging field of treatments.”
Lewis “Rusty” Williams, co-founder and CEO of Walking Fish Therapeutics
Author: Rare Daily Staff
Sign up for updates straight to your inbox.